Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730715 · ClinicalTrials.gov registry record
Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients
A clinical trial, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- 30
- Enrollment target
NCT02730715: Clinical Trial study, sponsored by University of Pennsylvania.
NCT02730715 is a clinical trial that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730715 was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study aims to study the effects that two standard of care immunosuppression induction regimens have on regulatory T cells (Treg) in live donor renal transplant recipients. Both regimens are currently used in this hospital for early immunosuppression induction but the effects on Treg numbers and function is not well understood and likely will impact long term immune function.
Interventions
- DRUG Thymoglobulin
- DRUG Basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-11 |
| Est. Completion | 2020-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730715
The ClinicalTrials.gov registry entry for NCT02730715 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thymoglobulin is the first listed.
NCT02730715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730715 about?
NCT02730715 is a clinical study titled "Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients". This study aims to study the effects that two standard of care immunosuppression induction regimens have on regulatory T cells (Treg) in live donor renal transplant recipients. Both regimens are currently used in this hospital for early immunosuppression induction but the effects on Treg numbers and...
What is the current status of trial NCT02730715?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2010-11. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02730715?
The interventions under investigation include: Thymoglobulin (DRUG), Basiliximab (DRUG).
Who is sponsoring clinical trial NCT02730715?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.